Xvivo presents positive data from heart preservation clinical trial

April 15, 2024

Xvivo has recently presented positive results from its NIHP2019 clinical trial. The primary analysis shows that serious complications after heart transplantation occurred in 18.8 per cent of patients who received a donated heart preserved with the company's system compared to 30.1 per cent in the control group where the transport was carried out according to the current standard method.

The result shows a clinically relevant reduction in primary cardiac dysfunction for patients transplanted with a donated heart preserved with Xvivo's system and is an important step towards the company's vision that no one should die waiting for a new organ.


Read the full press release here.